Literature DB >> 10191176

On the origin of multiple mutations in human cancers.

A L Jackson1, L A Loeb.   

Abstract

Tumor progression is a multi-step process, proceeding by multiple alterations from a normal cell to a localized tumor, and finally to one that acquires the ability to invade and metastasize. Tumors are characterized by many mutations in the form of base substitutions, deletions, chromosomal translocations, and gene amplifications, and these mutations are found to accumulate as tumors progress. In contrast, spontaneous mutations are very rare events. Considering the high fidelity of DNA replication in normal cells, it seems improbable that spontaneous mutations could be the source of the large numbers of genetic alterations that are observable in cancer cells. The question of how multiple mutations accumulate in tumor cells is one of considerable interest, since understanding the source of these mutations may facilitate the detection of tumors and may provide new approaches to cancer prevention. We have proposed that the multiple mutations detectable in cancer cells result from a mutator phenotype, in which loss of a genome stability function occurs early during tumor development and predisposes the tumor cell to the accumulation of further mutations. We will first consider the evidence that cancer cells manifest a mutator phenotype, and subsequently discuss the possibility that a mutator phenotype can be selected and can be transient as tumors progress. Copyright 1998 Academic Press.

Entities:  

Mesh:

Year:  1998        PMID: 10191176     DOI: 10.1006/scbi.1998.0113

Source DB:  PubMed          Journal:  Semin Cancer Biol        ISSN: 1044-579X            Impact factor:   15.707


  15 in total

1.  Horizontal transfer of oncogenes by uptake of apoptotic bodies.

Authors:  A Bergsmedh; A Szeles; M Henriksson; A Bratt; M J Folkman; A L Spetz; L Holmgren
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-15       Impact factor: 11.205

Review 2.  DNA replication fidelity in Escherichia coli: a multi-DNA polymerase affair.

Authors:  Iwona J Fijalkowska; Roel M Schaaper; Piotr Jonczyk
Journal:  FEMS Microbiol Rev       Date:  2012-04-05       Impact factor: 16.408

3.  Preface: chromosomal instability and breast cancer pathogenesis.

Authors:  Ashok R Venkitaraman
Journal:  J Mammary Gland Biol Neoplasia       Date:  2004-07       Impact factor: 2.673

Review 4.  Embryonic reversions and lineage infidelities in tumour cells: genome-based models and role of genetic instability.

Authors:  Leon P Bignold
Journal:  Int J Exp Pathol       Date:  2005-04       Impact factor: 1.925

5.  Inactivation of wild-type p53 tumor suppressor by electrophilic prostaglandins.

Authors:  P J Moos; K Edes; F A Fitzpatrick
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-01       Impact factor: 11.205

6.  p50(Cdc37) can buffer the temperature-sensitive properties of a mutant of Hck.

Authors:  G Scholz; S D Hartson; K Cartledge; N Hall; J Shao; A R Dunn; R L Matts
Journal:  Mol Cell Biol       Date:  2000-09       Impact factor: 4.272

7.  Impact of age on hypermutation of immunoglobulin variable genes in humans.

Authors:  K Rosner; D B Winter; C Kasmer; G L Skovgaard; R E Tarone; V A Bohr; P J Gearhart
Journal:  J Clin Immunol       Date:  2001-03       Impact factor: 8.317

8.  Evidence of genetic instability in tumors and normal nearby tissues.

Authors:  Giuseppe Geraci; Ida D'Elia; Rosanna del Gaudio; Rossella Di Giaimo
Journal:  PLoS One       Date:  2010-02-23       Impact factor: 3.240

9.  Extensive genetic variation in somatic human tissues.

Authors:  Maeve O'Huallachain; Konrad J Karczewski; Sherman M Weissman; Alexander Eckehart Urban; Michael P Snyder
Journal:  Proc Natl Acad Sci U S A       Date:  2012-10-05       Impact factor: 11.205

Review 10.  Systems biological and mechanistic modelling of radiation-induced cancer.

Authors:  M P Little; W F Heidenreich; S H Moolgavkar; H Schöllnberger; D C Thomas
Journal:  Radiat Environ Biophys       Date:  2007-12-21       Impact factor: 1.925

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.